Literature DB >> 19457565

Brachytherapy versus cystectomy in solitary bladder cancer: a case control, multicentre, East-Netherlands study.

Elzbieta van der Steen-Banasik1, Martine Ploeg, Johannes A Witjes, Farida S van Rey, Jan G Idema, Robert P Heijbroek, Herbert F Karthaus, Janny G Reinders, A Viddeleer, Andries G Visser.   

Abstract

PURPOSE: Comparing the outcome of surgery and brachytherapy-based radiotherapy in patients with solitary T1G3/T2 bladder tumour in, a retrospective case-control study, because efforts for a randomised clinical trial comparing these modalities have failed.
MATERIALS AND METHODS: Cystectomy group. Patients were selected using the pathological registration system (PALGA). 289 cases of TURT followed by cystectomy, indicated by a muscle--invading bladder tumour were performed in three East-Netherlands medical centres between 1991 and 2001. Out of this group 179 patients with clinical T2N0M0 bladder tumour were selected. All the consecutive files were analysed by a urologist and a radiation oncologist and 65 of those patients (mean age 63.7 years) would have been eligible for brachytherapy, based on an initial analysis: cystoscopy estimated tumour size, post-TURT pathological report, completed by CT-scan and/or, MRI-scan. A final pathological report after radical cystectomy was not considered for patients' selection. Brachytherapy group. Patients were selected using a prospective registration study aiming at determination of our treatment results. 89 Patients (mean age 68.4 years) underwent TURT followed by a course of external beam irradiation and interstitial brachytherapy from 1983 till 2005 in the Arnhem Radiotherapy Institute.
RESULTS: The median follow-up for the brachytherapy group was 5.7 years (range 0.2-21.4 years), for the cystectomy group was 5.05 years (range: 0.04-16.8 years). No difference in disease-specific survival (DSS) could be detected with a 5- and 10-year DSS of 71% and 66% in the brachytherapy group and 60% and 57% in the cystectomy group, respectively. Five-year overall survival (OS) was 57% in the brachytherapy group and 52% in the cystectomy group, however, the 10-year OS was better in the cystectomy than in the brachytherapy group (42% and 33%, respectively). This is caused by the significant age difference in favour of the cystectomy group. Cystectomy-free survival in the brachytherapy group was 70%.
CONCLUSION: Radical cystectomy is the treatment of choice for patients with muscle-invasive bladder carcinoma. However, in a selected patient population a bladder sparing treatment, i.e. a combination of transurethral tumour resection (TURT), external beam irradiation and interstitial brachytherapy, can be applied successfully. This concerns a solitary, T1G3 or T2 bladder tumour, with a diameter<5 cm.

Entities:  

Mesh:

Year:  2009        PMID: 19457565     DOI: 10.1016/j.radonc.2009.04.020

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  11 in total

Review 1.  [Radiochemotherapy for invasive bladder cancer : An update].

Authors:  N Tselis; F J Prott; O Ott; C Weiss; C Rödel
Journal:  Urologe A       Date:  2018-06       Impact factor: 0.639

2.  Treatment and outcome in muscle invasive bladder cancer: a population-based survey.

Authors:  Anna M Leliveld; Benjamin H J Doornweerd; Esther Bastiaannet; Michael Schaapveld; Igle J de Jong
Journal:  World J Urol       Date:  2010-04-10       Impact factor: 4.226

Review 3.  Multimodal management of muscle-invasive bladder cancer.

Authors:  Jong Chul Park; Deborah E Citrin; Piyush K Agarwal; Andrea B Apolo
Journal:  Curr Probl Cancer       Date:  2014-06-23       Impact factor: 3.187

4.  Comparative survival following different treatment modalities for stage T2 bladder cancer in octogenarians.

Authors:  Jerry J Trulson; Pranav Sharma; Tyler Haden; Emil Kheterpal; Naveen Pokala
Journal:  World J Urol       Date:  2013-07-02       Impact factor: 4.226

5.  Patterns of care study for brachytherapy: results of the questionnaire for the years 2002 and 2007 in The Netherlands.

Authors:  Jack L M Venselaar; Ben J Slotman; Ferran Guedea; Montse Ventura; Bradley Londres; Guy Francois
Journal:  J Contemp Brachytherapy       Date:  2011-01-14

Review 6.  Intraoperative radiotherapy in gynaecological and genito-urinary malignancies: focus on endometrial, cervical, renal, bladder and prostate cancers.

Authors:  Marco Krengli; Carla Pisani; Letizia Deantonio; Daniela Surico; Alessandro Volpe; Nicola Surico; Carlo Terrone
Journal:  Radiat Oncol       Date:  2017-01-19       Impact factor: 3.481

7.  Don't forget the bladder!

Authors:  Bernard J Oosterveld; Elzbieta M van der Steen-Banasik; Geert A Smits
Journal:  J Contemp Brachytherapy       Date:  2018-04-30

8.  Robotic transmural ablation of bladder tumors using high-intensity focused ultrasound: Experimental study.

Authors:  Andre Luis de Castro Abreu; Osamu Ukimura; Sunao Shoji; Scott Leslie; Sameer Chopra; Arnaud Marien; Toru Matsugasumi; Arjuna Dharmaraja; Kelvin Wong; Natalie Zaba; Yanling Ma; Mihir M Desai; Inderbir S Gill
Journal:  Int J Urol       Date:  2016-04-01       Impact factor: 3.369

Review 9.  Bladder preservation with brachytherapy compared to cystectomy for T1-T3 muscle-invasive bladder cancer: a systematic review.

Authors:  Manouk K Bos; Rafael Ordoñez Marmolejo; Coen R N Rasch; Bradley R Pieters
Journal:  J Contemp Brachytherapy       Date:  2014-06-28

Review 10.  Bladder Preservation for Muscle Invasive Bladder Cancer.

Authors:  Arafat Mirza; Ananya Choudhury
Journal:  Bladder Cancer       Date:  2016-04-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.